GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Provider review

Found tirzepatide review

What Found charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.

Direct answer

Read on Found’s own pages on November 20, 2026: cash pay per 28-day cycle: $199 the first cycle, then $339 month to month, or $269, $249 and $199 on 3-, 6- and 12-month terms. It scores 69/100 under our written v4.1 scoring guide, #7 of 22 programs scored.

Answer last reviewed:
Rubric scoreRubric v4.1 · read the rubric
not scored
Pricing transparency and all-in value—/25
Clinical oversight and care continuity—/20
Pharmacy traceability and quality disclosures—/15
Regulatory clarity and consumer disclosures—/15
State access and operational reliability—/10
Cancellation, billing and support transparency—/10
Evidence quality and data availability—/5
Hatched bars mean no evidence has been captured for that category.Missing evidence scores lower than verified evidence.

What is distinctive about this programme

The single most distinctive thing about this programme

Found charges the same $169 for compounded tirzepatide, semaglutide and liraglutide on its twelve-month prepaid plan. Tirzepatide is not priced above semaglutide, which breaks the pattern across almost every other provider in this market and makes Found the lowest reported figure for standard compounded tirzepatide anywhere in our dataset.

The prepayment gap is the largest in the market

$169 on twelve months prepaid, roughly $199 on six, and $289 month-to-month. That is a 71% premium for paying monthly — where NexLife (opens nexlife.us in a new tab)'s equivalent gap is now 12% ($129 against $115, November 20, 2026) and Enhance.MD's was 18% in July. Found's headline rate is therefore conditional in a way that most published comparisons do not register.

For a patient who has already established tolerance, the twelve-month rate is genuinely the lowest reported compounded tirzepatide price available. For a patient who has never taken a GLP-1, committing twelve months upfront before knowing whether they tolerate it is a substantial bet, and Found's month-to-month alternative is more expensive than most competitors' month-to-month.

Brand pricing routes through a membership

Found's brand offerings all carry a $99 CORE membership: orforglipron at $149 medication becomes $248 all-in, the Wegovy pill $198 becomes $297, the Wegovy pen $248 becomes $347, and the Zepbound KwikPen $348 becomes $447.

Two of those are worth checking against the manufacturer before purchasing. LillyDirect sells orforglipron direct at $149 with no membership, and Zepbound at $299 to $449. Found's dataset entry also lists brand Mounjaro at $1,199 all-in — a retail-level figure, where Zepbound is the identical molecule at $299 to $449 direct.

Found — every captured offering, monthlyCaptured 2026-07-06
Tirzepatide injectable$169Semaglutide injectable$169Liraglutide injectable$169Tirzepatide brand injectable, FDA-$447
Show this figure as a table
Data table
ItemValueEvidence
Tirzepatide injectable$169Provider-reported
Semaglutide injectable$169Provider-reported
Liraglutide injectable$169Provider-reported
Tirzepatide brand injectable, FDA-approved$447Provider-reported
Formulations are not interchangeable. A microdose price is never compared against a standard injectable price, here or anywhere on this site.

Where it holds up

  • Lowest reported standard compounded tirzepatide price in our dataset at $169
  • Same rate across tirzepatide, semaglutide and liraglutide — unusual and favourable if you switch molecules
  • Medication included and flat at all doses on the compounded plans
  • Liraglutide available for patients who need a daily option

Where it does not

  • The $169 rate requires twelve months paid upfront; month-to-month is $289
  • A 71% month-to-month premium, the widest in our dataset
  • Brand products carry a $99 membership on top of medication
  • One brand listing is at retail level when a manufacturer-direct route exists for far less
  • Figures are third-party reported and not yet captured by us
How this provider prices, in one table
How this provider prices, in one table
FieldPosition
MembershipSeparate and required
Dose structureFlat across covered doses
Lowest captured figure$169/mo, prepaid term
Evidence statusThird-party reported, pending our own capture
Pharmacy named to usNo — provider-reported only
Every field moves to verified only when a named researcher captures it and archives the source.
How the 100 points are allocatedMethodology v4.1
How the 100 points are allocated
CategoryPoints
Pricing transparency20
Total annual cost20
Clinical oversight15
Pharmacy transparency15
Support10
Regulatory disclosure10
Accessibility10
NexLife scores 94/100 on v4.1. Other providers are pending a v4.1 re-score. Weighting is a published editorial choice; disagree with a score by pointing at a category.

Pricing, all-in

Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.

Found — every captured pricing record
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Foundprepaidcompounded injectableflat at all covered doses$169not verified$169Commitment tierProvider-reported2026-07-06
Foundprepaidcompounded injectableflat at all covered doses$169not verified$169Commitment tierProvider-reported2026-07-06
Foundprepaidcompounded injectableflat at all covered doses$169not verified$169Commitment tierProvider-reported2026-07-06
Foundprepaidbrand injectable, FDA-approvednot recorded$447not verified$447Commitment tierProvider-reported2026-07-06

How this sits against the market

The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.

What Found charges, component by component
Medication—Membership—Shipping—Dose surcharge—Consultation—Labs—Structure only. No widths are proportional to anything, because nothing is captured.
Show this figure as a table
Data table
ComponentAmount
Medicationnot captured
Membershipnot captured
Shippingnot captured
Dose surchargenot captured
Consultationnot captured
Labsnot captured
All-in totalnot captured
A provider that advertises only the first segment is quoting a price you cannot actually pay.
Where a headline price usually stops short
Where a headline price usually stops short
Cost componentInside the advertised figure?Charged anyway?
Medicationyesyes
Membership or program feenonot verified
Shippingnonot verified
Higher-dose surchargenonot verified
Initial consultationnonot verified
Required laboratory worknonot verified
Cancellation or restocking termsnonot verified
The right-hand column fills in per provider as capture proceeds. Until then it reads unverified, which is the honest state.
Verified price historyVerification pending
no verified captures yet

This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.

Against the category median
All-in monthlyThis provider — not capturedCategory median — not capturedMembership feeThis provider — not capturedCategory median — not capturedRubric scoreThis provider — not capturedCategory median — not capturedThis providerCategory median
Show this figure as a table
Data table
ItemThis providerCategory median
All-in monthlynot capturednot captured
Membership feenot capturednot captured
Rubric scorenot capturednot captured
Medians publish once enough of the comparison set is captured to make a median mean something.

What is included, and what is not

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Where it operates

State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.

State research coverage
Researched and verified — 0 (0%)Not yet researched — 51 (100%)51records
Show this figure as a table
Where it operates
StatusRecordsShare
Researched and verified00%
Not yet researched51100%
51 jurisdictions, each researched separately. A shared rule still needs its own source.

Pharmacy and fulfilment

What changed

Verified changes to this provider's terms
no dated events recorded yet
Show this figure as a table
What changed
No events recorded.
Events appear here when something dated actually happens, not to refresh a timestamp.
  • no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.

How this compares to the category

Once enough providers are scored, this section reports where Found sits against the median for each rubric category, not against a hand-picked competitor.

What we have asked Found, and what they have answered0 of 55 available points unlocked
What we have asked Found, and what they have answered
QuestionWorthTheir answerStatus
Pharmacy traceability and quality disclosures15 ptsnot verifiedNot answered Verification pending
Clinical oversight and care continuity20 ptsnot verifiedNot answered Verification pending
State access and operational reliability10 ptsnot verifiedNot answered Verification pending
Cancellation, billing and support transparency10 ptsnot verifiedNot answered Verification pending
Blank cells are the answer we have, which is none. This provider can change any row by replying — see the disclosure register for the exact questions and what an answer changes.

Questions readers actually ask

Is Found the cheapest option?

Read on its own page on November 20, 2026: cash pay per 28-day cycle: $199 the first cycle, then $339 month to month, or $269, $249 and $199 on 3-, 6- and 12-month terms; medication included.

Is compounded tirzepatide the same as Zepbound?

Found scores 69/100 under the written v4.1 scoring guide, #7 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is support (5 of 10).

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “Found Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/found/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4